Is nivolumab a chemotherapy drug or a targeted drug?

Nivolumab (Nivolumab) is an immune checkpoint inhibitor, a type of targeted immunotherapy, rather than a traditional chemotherapy drug. Unlike traditional chemotherapy drugs, nivolumab treats cancer by modulating the function of the immune system rather than directly attacking cancer cells.

Immune checkpoint inhibitors activate the patient's own immune system by blocking the signaling pathways on immune checkpoints, thereby enhancing the immune system's ability to recognize and eliminate cancer cells. Nivolumab mainly targets the PD-1 (programmed death-1) receptor, an immune checkpoint protein whose normal function is to prevent T cells from attacking normal tissue cells to avoid autoimmune reactions. However, cancer cells can exploit the PD-1 pathway to evade immune system attack. Nivolumab works by blocking the binding of PD-1 and its ligand PD-L1 (programmed death ligand -1), thereby restoring the ability of T cells to attack cancer cells and enhancing the immune response.

Nivolumab has been approved to treat a variety of cancers, including advanced non-small cell lung cancer, melanoma, renal cell carcinoma, Hodgkin lymphoma, and head and neck squamous cell carcinoma. In many clinical trials, nivolumab has shown significant efficacy, including improved patient survival and quality of life. It is often used as a single agent or in combination with other drugs to treat advanced or metastatic cancer, especially in patients who have received other treatments without satisfactory results.

In general, nivolumab, as a targeted immunotherapy, has brought new treatment options to many cancer patients. Its efficacy has been fully verified in clinical practice, bringing important breakthroughs and progress in the field of cancer treatment.